Home > Gastroenterology > ECCO 2022 > Head-to-Head Comparisons > Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By
Dr Neeraj Narula, McMaster University, Canada
ECCO 2022
A post-hoc analysis of pivotal clinical trials showed that the TNF inhibitors adalimumab and infliximab generally outperformed vedolizumab and ustekinumab with regard to endoscopic healing of the ileum and colon in participants with Crohn’s disease (CD). However, in biologic-naïve participants, TNFs and ustekinumab did not display significant differences for endoscopic healing of the colon. Recent evidence has demonstrated that large ulcers of the ileum and rectum are less likely to heal with infliximab compared with other biologic therapies. In addition, no trials have been conducted to compare biologic therapies for ileal and colonic healing in patients with CD. Dr Neeraj Narula (McMaster University, Canada) and colleagues performed a pooled analysis that included 344 participants with CD who were enrolled in clinical trials [1]. All participants had received continuous adalimumab, infliximab, ustekinumab, or vedolizumab. The primary endpoint was ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on